Colorectal liver metastases (CRLM), cancer that has spread from the colon or rectum to the liver, have a deadly reputation.
BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in ...
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
Metastatic Colorectal Cancer Market Global Assessment Report 2026 To 2035. February 17, 2026 11:36 pm - Global Metastatic Colorectal Cancer Market Size is valued at USD 7.68 Bn in 2025 and is ...
Cells from cancerous tumors can spread, or metastasize, throughout the body. Researchers have long sought to understand what determines where those cells will go and thrive in order to more ...
The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...
Exelixis, Inc. (Nasdaq: EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for review in the U.S. for the ...
The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic ...
Colorectal cancer is now the deadliest cancer for young adults, surpassing other types. Learn about the alarming trend and ...
Pfizer Inc. PFE shares are trending on Wednesday following the U.S. Food and Drug Administration’s (FDA) full approval of the ...
Review highlights how transplant oncology is expanding liver transplantation for selected primary and metastatic liver ...
Delcath Systems, Inc.’s Q3 revenue was pressured by weak patient starts, but 2026 growth prospects remain strong. Click for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results